Glucagon and insulin hypoglycaemia

Similar glycaemic control and risk of hypoglycaemia with patient- versus physician-managed titration of insulin glargine 300 U/mL across subgroups of patients with T2DM: a post hoc analysis of ITAS.

Acta diabetologica·2021

Italian Titration Approach Study (ITAS) with insulin glargine 300 U/mL in insulin-naïve type 2 diabetes: Design and population.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2019

Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.

Diabetes & metabolism·2018

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes.

Diabetes & metabolism·2018

Assessment of hypoglycaemia during basal insulin therapy: Temporal distribution and risk of events using a predefined or an expanded definition of nocturnal events.

Diabetes & metabolism·2017

Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes.

Diabetes & metabolism·2017

Dementia in type 2 diabetes: risk factors, disease processes and opportunities for prevention across the lifespan.

Diabetologia·2026

Premeal insulin administration lowers postprandial blood glucose and increases myocardial microvascular blood flow in people with type 1 diabetes: a randomised, crossover clinical trial.

Diabetologia·2026

Age-independent immune subtypes in type 1 diabetes exhibit distinct post-onset progression rates and immunotherapeutic responses.

Diabetologia·2026

Islet ultrastructure: past achievements and future directions.

Diabetologia·2026

Unhealthy fat distribution as a sex-specific predictor of declining hippocampus insulin sensitivity.

Diabetologia·2026

Baseline and longitudinal joint associations of alcohol consumption and obesity with diabetes risk: evaluating multiplicative and additive interactions.

Diabetologia·2026

Cuproptosis-related Gene SLC31A1 Correlates with M2 Macrophage Infiltration and Serves as a Potential Therapeutic Target in Glioma: A Comprehensive Analysis of 1573 Samples from TCGA and CGGA Databases.

Recent patents on anti-cancer drug discovery·2026

Statistical analysis plan considerations for autologous cell and cell-based gene therapy clinical trials.

Journal of biopharmaceutical statistics·2026

Designs of the clinical trials aiming at evaluating cell and gene therapy products: A critical appraisal from a literature review.

Molecular therapy. Advances·2026

Longitudinal drug response assessment of tumor organoids based on optical attenuation coefficient and multi-dimensional morphological characterization.

Biomedical optics express·2026

Nanosensitive optical coherence tomography to monitor corneal burn and treatment response in vivo.

Biomedical optics express·2026

Contemporary perspectives on metabolic surgery for type 2 diabetes: surgical techniques, outcomes, and complications.

Frontiers in endocrinology·2026

Related Experiment Videos

Glucagon and insulin hypoglycaemia

Related Concept Videos

Similar glycaemic control and risk of hypoglycaemia with patient- versus physician-managed titration of insulin glargine 300 U/mL across subgroups of patients with T2DM: a post hoc analysis of ITAS.

Italian Titration Approach Study (ITAS) with insulin glargine 300 U/mL in insulin-naïve type 2 diabetes: Design and population.

Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes.

Assessment of hypoglycaemia during basal insulin therapy: Temporal distribution and risk of events using a predefined or an expanded definition of nocturnal events.

Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes.

Dementia in type 2 diabetes: risk factors, disease processes and opportunities for prevention across the lifespan.

Premeal insulin administration lowers postprandial blood glucose and increases myocardial microvascular blood flow in people with type 1 diabetes: a randomised, crossover clinical trial.

Age-independent immune subtypes in type 1 diabetes exhibit distinct post-onset progression rates and immunotherapeutic responses.

Islet ultrastructure: past achievements and future directions.

Unhealthy fat distribution as a sex-specific predictor of declining hippocampus insulin sensitivity.

Baseline and longitudinal joint associations of alcohol consumption and obesity with diabetes risk: evaluating multiplicative and additive interactions.

Cuproptosis-related Gene SLC31A1 Correlates with M2 Macrophage Infiltration and Serves as a Potential Therapeutic Target in Glioma: A Comprehensive Analysis of 1573 Samples from TCGA and CGGA Databases.

Statistical analysis plan considerations for autologous cell and cell-based gene therapy clinical trials.

Designs of the clinical trials aiming at evaluating cell and gene therapy products: A critical appraisal from a literature review.

Longitudinal drug response assessment of tumor organoids based on optical attenuation coefficient and multi-dimensional morphological characterization.

Nanosensitive optical coherence tomography to monitor corneal burn and treatment response in vivo.

Contemporary perspectives on metabolic surgery for type 2 diabetes: surgical techniques, outcomes, and complications.

Related Experiment Videos

Glucagon and insulin hypoglycaemia

Related Concept Videos

Related Articles